Clinical and Diagnostic Features and Treatment Outcomes of Locally Advanced Medullary Thyroid Carcinoma in the Tyumen Region, Russia
Open Access
- 3 July 2026
- journal article
- Published by Bashkir State Medical University in Creative surgery and oncology
- Vol. 16 (2) , 162-170
Abstract
Introduction. Medullary thyroid carcinoma (MTC) is a rare and aggressive malignancy, accounting for 2–5% of all thyroid cancers. Aim. This study examined the epidemiological profile of MTC in the Tyumen Region (Russia) and evaluated the effectiveness and tolerability of multikinase inhibitors (MKIs) in MTC therapy. Materials and methods. The analysis included 69 patients with MTC treated between 2017 and 2025. Patient age ranged from 39 to 78 years (median 57). Sonographic characteristics of thyroid nodules were classified according to the EU-TIRADS. Cytological evaluation of fine-needle aspiration samples followed the Bethesda Thyroid Classification (2009, 2017, 2023). Survival outcomes were calculated using the Kaplan–Meier method. Serum calcitonin (CT) and carcinoembryonic antigen (CEA) levels were measured by electrochemiluminescence. RET mutation testing was performed on blood samples and, in one case, on surgical tissue. Results . Between 2017 and 2025, peak MTC incidence in the Tyumen Region occurred in 2021 and 2024, reaching 0.65 and 0.74 per 100,000 population, respectively. During cabozantinib therapy, mean survival was 19.30 months (95% CI 14.45–21.39), with a median of 17.01 months. For vandetanib in first-line therapy, mean survival was 18 months (95% CI 12.57–23.59), with a median of 14.00 months (95% CI 12.46–20.55). The objective response rate was 29.4% with vandetanib and 36.8% with cabozantinib. The most frequent adverse events were arterial hypertension with vandetanib, palmar-plantar erythrodysesthesia with cabozantinib, and toxic hepatitis with selpercatinib. Discussion. This retrospective analysis demonstrates the effectiveness and safety of MKIs in routine clinical practice. Cabozantinib showed superior survival outcomes and objective response rates compared to vandetanib. The observed adverse events were expected and manageable. The findings are consistent with published clinical evidence. Conclusion . Given the aggressive nature of MTC, continuous monitoring of disease progression is essential. In cases of progression, MKI therapy should be considered, with careful evaluation of potential toxicity in relation to individual treatment goals.Keywords
This publication has 28 references indexed in Scilit:
- 1913O Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC)Annals of Oncology, 2020
- Efficacy of Selpercatinib in RET -Altered Thyroid CancersNew England Journal of Medicine, 2020
- Long-term follow-up and safety of vandetanib for advanced medullary thyroid cancerEndocrine, 2020
- Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted SequencingiScience, 2019
- Targeting Hypoxia-Inducible Factors for Antiangiogenic Cancer TherapyTrends in Cancer, 2017
- A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU studyEuropean Journal of Cancer, 2017
- Lenvatinib: Role in thyroid cancer and other solid tumorsCancer Treatment Reviews, 2016
- The cAMP analogs have potent anti-proliferative effects on medullary thyroid cancer cell linesEndocrine, 2015
- Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid CancerNew England Journal of Medicine, 2015
- Lokales Amyloid der SchilddrüseVirchows Archiv, 1910